World's Best Scientists 2026 revealed!
Lori S. Friedman

Lori S. Friedman

D-Index & Metrics

Biology and Biochemistry

D-Index
67
Citations
20866
World Ranking
8088
National Ranking
3663

Overview

Lori S. Friedman is a researcher affiliated with Genentech in the United States. Their work spans several fields primarily within medicine and biochemistry, genetics, and molecular biology. The main areas of scientific study for this researcher include pulmonary and respiratory medicine, oncology, molecular biology, genetics, and physiology.

The scientist's research topics focus notably on:

  • Estrogen and related hormone effects
  • Advanced breast cancer therapies
  • Adenosine and purinergic signaling
  • Prostate cancer treatment and research
  • HER2/EGFR in cancer research
  • PI3K/AKT/mTOR signaling in cancer
  • Peptidase inhibition and analysis

Publications by Lori S. Friedman appear frequently in a number of scientific journals. The most common venues include:

  • Cancer Research (22 publications)
  • Journal of Medicinal Chemistry (4 publications)
  • Molecular Cancer Therapeutics (3 publications)
  • European Journal of Cancer (2 publications)
  • Blood (2 publications)

Representative recent papers demonstrate the scope of their work:

  • GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer, 2021, Journal of Medicinal Chemistry
  • Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα, 2022, Journal of Medicinal Chemistry
  • Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3, 2020, Journal for ImmunoTherapy of Cancer
  • Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production, 2020, Journal of Medicinal Chemistry
  • Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer, 2020, ACS Medicinal Chemistry Letters

Frequent collaborators in their research include:

  • Melissa R. Junttila
  • Anneleen Daemen
  • Natalie Yuen
  • Frank Duong
  • Jessica D. Sun

Best Publications

  • RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

    Georgia Hatzivassiliou;Kyung Song;Ivana Yen;Barbara J. Brandhuber

  • The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†

    Adrian J. Folkes;Khatereh Ahmadi;Wendy K. Alderton;Sonia Alix

  • Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

    Teemu T. Junttila;Robert W. Akita;Kathryn Parsons;Carter Fields

  • Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome

    Annette L Parks;Kevin R Cook;Marcia Belvin;Nicholas A Dompe

  • Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families

    Lori S. Friedman;Elizabeth A. Ostermeyer;Csilla I. Szabo;Patrick Dowd

  • Involvement of Brca2 in DNA repair.

    Ketan J Patel;Veronica P.C.C Yu;Hyunsook Lee;Anne Corcoran

  • Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

    Khaled Ali;Dalya R. Soond;Roberto Piñeiro;Thorsten Hagemann

  • A Collaborative Survey of 80 Mutations in the BRCA1 Breast and Ovarian Cancer Susceptibility Gene: Implications for Presymptomatic Testing and Screening

    Donna Shattuck Eidens;Melody Mcclure;Jacques Simard;Fernand Labrie

  • In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

    Klaus P. Hoeflich;Carol O'Brien;Zachary Boyd;Guy Cavet

  • Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents

    Michael Degtyarev;Ann De Mazière;Christine Orr;Jie Lin

  • Drosophila p53 Is a Structural and Functional Homolog of the Tumor Suppressor p53

    Michael Ollmann;Lynn M Young;Charles J Di Como;Felix Karim

  • Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population

    L. S. Friedman;S. A. Gayther;T. Kurosaki;D. Gordon

  • Closing in on a breast cancer gene on chromosome 17q.

    J M Hall;L Friedman;C Guenther;M K Lee

  • Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

    Georgia Hatzivassiliou;Jacob R. Haling;Huifen Chen;Kyung Song

  • First-in-human Phase I study of Pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors

    Debashis Sarker;Debashis Sarker;Joo Ern Ang;Joo Ern Ang;Richard Douglas Baird;Richard Douglas Baird;Rebecca Kristeleit;Rebecca Kristeleit

  • Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

    Carol O'Brien;Jeffrey J. Wallin;Deepak Sampath;Debraj GuhaThakurta

  • Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

    Martin L. Sos;Stefanie Fischer;Roland Ullrich;Martin Peifer

  • Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

    Jie Lin;Deepak Sampath;Michelle A. Nannini;Brian B. Lee

  • GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

    Jeffrey J. Wallin;Kyle A. Edgar;Jane Guan;Megan Berry

  • Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer

    Daniel P. Sutherlin;Linda Bao;Megan Berry;Georgette Castanedo

Frequent Co-Authors

Mary Claire King
Mary Claire King University of Washington
adrian l harris
adrian l harris University of Oxford
Bruce A.J. Ponder
Bruce A.J. Ponder University of Cambridge
Bart Vanhaesebroeck
Bart Vanhaesebroeck University College London
Christian Wiesmann
Christian Wiesmann Novartis (Switzerland)
Ming K. Lee
Ming K. Lee University of Washington
Florian Gnad
Florian Gnad Roche (Germany)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry can open doors to a variety of careers in healthcare, research, and information management. Many students consider online degrees for flexibility and affordability, especially in fields like health information management and nutrition.

For those interested in healthcare administration, a bachelor's degree health information management offers a pathway to roles such as medical coder or medical biller. These careers have become increasingly popular due to strong job prospects and the ability to work remotely. It’s important to understand the medical coder salary ranges and the medical billing and coding outlook before deciding on your educational path.

Additionally, those focused on biochemistry and health may pursue advanced studies. The cost of masters degree in nutrition can be surprisingly affordable when completed online, making further specialization accessible for many students.

Whether you are seeking clinical, administrative, or research opportunities, the right online degree can help you launch a rewarding career in the biological sciences.

Best Scientists Citing Lori S. Friedman

Trending Scientists

Recently Published Articles